Through innovative research on cancer treatment and prevention, members of the UBC Faculty of Medicine are attacking cancer on several fronts. Building from a rich tradition of discovery science, our people and partners are taking hold of new technologies and are exploring new areas of research to advance knowledge and improve care.

Skip to Stories


Bringing a new cancer drug to market

Two decades ago, Poul Sorensen made a discovery that would lead to the development of a cancer drug that shrinks many different kinds of tumours.
Read more >

Novel discovery could lead to new cancer, autoimmune disease therapy

International research project co-led by UBC Canada 150 Research Chair.
Read more >

Rare but recurring mutations discovered in ER-positive breast cancer

The uncommon mutations were associated with early relapse and death, and thus stand out as therapeutic targets.
Read more >

UBC bestows national prizes on Canadian health science pioneers

Andrew Krahn, Bruce McManus, Kullervo Hynynen and Martin Gleave are being honoured for their accomplishments in heart health, brain health and cancer.
Read more >

HPV test better than Pap test at detecting cervical precancer

A study of 19,000 women in British Columbia showed that the HPV test finds precancer sooner.
Read more >

“Arms race” between cancer and immune system revealed

The study led by MD/PhD student Allen Zhang will assist the design of new immunotherapy trials.
Read more >

UBC leads Canadian pancreatic cancer research initiative

The $5 million project will sequence metastatic pancreatic tumours of 400 patients, looking to see if the primary cancers genetically differ from metastatic cancers.
Read more >

An under-the-radar immune cell shows potential in fight against cancer

ILC2 cells were discovered as a major player in asthma. Wilf Jefferies found they may also stop cancer from metastasizing.
Read more >

Do men’s toenails contain clues about prostate cancer prevention?

Researchers will analyze concentrations of toxic metals and look for correlations with the histories of prostate cancer patients.
Read more >

An unexpected target — and weapon — for one of the deadliest cancers

A new drug, fostamatinib, reduced the growth rate of esophageal adenocarcinoma in mice by at least 70 per cent.
Read more >